Travelers who are allergic to a vaccine component or who elect not to receive vaccine should receive a single dose of immune globulin (0.02 mL/kg), which provides effective protection against hepatitis A for up to 3 months. Travelers whose travel period exceeds 2 months should be administered immune globulin at 0.06 mL/kg; administration must be repeated if the travel period exceeds 5 months.

The federal government is not recommending that members of the general public be vaccinated at this point. Our government has no information that a biological attack is imminent, and there are significant side effects and risks associated with the vaccine.

There are vaccines that can keep you from getting Hepatitis A or Hepatitis B. There is currently no vaccine for Hepatitis C. The vaccine for Hepatitis A consists of two shots over 6 months. The Hepatitis B vaccine consists of 3 shots over 5-6 months. To get full protection (immunity) against Hepatitis A or B, you must get all of the shots in each series. Almost everyone infected with Hepatitis A completely recovers in about 4 to 8 weeks. There is no medication for Hepatitis A.

If you fall into any of the following groups, you should consult with your health professional about getting vaccinated against HAV: Children, two years of age and older, who live in areas with historically increased rates of Hepatitis A (for information about these areas, contact your local health department). Uinta County is a moderately at risk area. People who travel or work in any area of the world except the U.S., Canada, Western Europe, Japan, New Zealand, and Australia.

Yes, hepatitis A vaccine has an excellent safety profile. No serious adverse events have been attributed definitively to hepatitis A vaccine. Soreness at the injection site is the most frequently reported side effect. Any adverse event suspected to be associated with hepatitis A vaccination should be reported to the Vaccine Adverse Events Reporting System (VAERS). VAERS forms can be obtained by calling 1-800-822-7967.

Yes. Since Wilson's Disease often affects the liver, many Wilson's Disease patients cannot afford additional injury to the liver. Hepatitis A or Hepatitis B vaccine is as safe for Wilson's Disease patients as it is for others. Review of the literature and personal experience indicate that women successfully treated with either penicillamine, trientine or zinc uninterruptedly, have excellent chances for carrying through uncomplicated pregnancies and for delivering normal babies.

Yes, neither pregnancy nor breastfeeding should be considered a contraindication to vaccination of women. On the basis of limited experience, there is no apparent risk of adverse effects to developing fetuses when hepatitis B vaccine is administered to pregnant women. The vaccine contains noninfectious HBsAg particles and should cause no risk to the fetus. HBV infection affecting a pregnant woman might result in severe disease for the mother and chronic HBV infection for the newborn.

No, there is no vaccine for hepatitis C. Research is many years away from such a development or treatment. However, vaccines exist for hepatitis A and B. All patients with hepatitis C should have these vaccines.

Can hepatitis A vaccine be given to immunocompromised persons persons? (e.g., persons on hemodialysis or persons with AIDS)

The second dose should be administered as soon as possible. There is no need to repeat the first dose. Can hepatitis A vaccine be given during pregnancy or lactation? We don't know for sure, but because vaccine is produced from inactivated hepatitis A virus, the theoretical risk to the developing fetus is expected to be low. The risk associated with vaccination, however, should be weighed against the risk for hepatitis A in women who may be at high risk for exposure to hepatitis A virus.

All susceptible persons traveling to or working in countries that have high or intermediate rates of hepatitis A should be vaccinated or receive immune globulin before traveling. Persons from developed countries who travel to developing countries are at high risk for hepatitis A. Such persons include tourists, military personnel, missionaries, and others who work or study abroad in countries that have high or intermediate levels of of hepatitis A.

Students attending grades kindergarten through third grade in the following 40 counties are required to have two doses of hepatitis A vaccine: Bexar, Brewster, Brooks, Cameron, Crockett, Culberson, Dimmitt, Duval, Edwards, El Paso, Frio, Gonzales, Grayson, Hidalgo, Hudspeth, Jeff Davis, Jim Hogg, Kenedy, Kinney, La Salle, Maverick, McMullen, Moore, Nueces, Pecos, Potter, Presidio, Randall, Real, Reeves, Starr, Sutton, Terrell, Terry, Uvalde, Val Verde, Webb, Willacy, Zapata, and Zavala counties.

The safety of hepatitis A vaccination during pregnancy has not been determined; however, because vaccine is produced from inactivated hepatitis A virus, the theoretical risk to the developing fetus is expected to be low. The risk associated with vaccination, however, should be weighed against the risk for hepatitis A in women who might be at high risk for exposure to hepatitis A virus. Yes.

A serious allergic reaction to a prior dose of hepatitis B vaccine or a vaccine component is a contraindication to further doses of hepatitis b vaccine. The recombinant vaccines that are licensed for use in the United States are synthesized by Saccharomyces cerevisiae (common bakers' yeast), into which a plasmid containing the gene for HBsAg has been inserted.

That will depend on IF and how long the FDA takes to review the exception approval we are seeking. If they approve our request, we could have the rubella vaccine in the US within 2 months of their approval.

Yes. If a person has a positive antibody test, he or she should then have a viral test. This is usually called a PCR test. This type of test is looking for the actual virus, rather than the antibodies and can tell if there is any hepatitis C in that person's body. If the PCR test is negative, that means that the person has cleared the virus and is no longer infected. If the PCR test is positive, that means that the person still has active hepatitis C.

This is a statistical estimate based on prior experience with the vaccine. However, we will work hard to prevent even these rare events from happening. Severe reactions can be minimized by screening people for bars to vaccination before vaccinating them and closely monitoring individuals for severe reactions with prompt treatment as necessary.

The hepatitis B vaccine is effective in preventing 95% of children and adults from developing chronic hepatitis B infection. It is not a treatment for those who have already been infected with hepatitis B.

Hepatitis A is spread through contaminated food and water. Hepatitis A is present in the U.S. The vaccine for Hepatitis A is very effective. You would get your first shot at the time of your visit and that will give immunity for 1 year. A booster at 6-12 months will give you long term protection. Hepatitis B is spread through blood and body fluids.

If the vaccination series is interrupted after the first dose, the second dose should be administered as soon as possible. The second and third doses should be separated by an interval of at least 2 months. If only the third dose is delayed, it should be administered when convenient.

Recent studies indicate that immunologic memory remains intact for at least 23 years and confers protection against clinical illness and chronic HBV infection, even though anti-HBs levels might become low or decline below detectable levels.

Yes. After a person has been exposed to HBV, appropriate treatment, given in an appropriate time frame, can effectively prevent infection. The mainstay of post exposure immunoprophylaxis is hepatitis B vaccine, but in some settings the addition of HBIG will provide some increase in protection.

We encourage all students to be immunized for Hepatitis B. After paying the cashier in the Administration Building $25.00 for the vaccine, bring your receipt to the health center to receive the vaccine.

Many studies have shown that Hepatitis A vaccine is very safe. Since 1995, more than seven million doses of Hepatitis A vaccine have been given in the U.S. with no report of serious health problems linked to the vaccine. Side effects might include soreness at the injection site, headache, and tiredness. These symptoms, if they occur, last for only a short time.